Spirits maker Diageo North America and pharmaceutical giant Pfizer Inc. (NYSE:PFE) have each agreed to pay a $5,000 fine because their lobbyists failed to disclose expenditures for receptions at the 2012 Democratic National Convention, the Office of State Ethics announced. Pfizer Inc. (NYSE:PFE) stock performance was 1.35% in last session and finished the day at $30.08. Traded volume was 25.60million shares in the last session and the average volume of the stock remained 29.08million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

MannKind Corporation (NASDAQ:MNKD), the Valencia company that last week won approval to market an inhalable form of insulin to people with diabetes, saw its shares climb 10% on Monday. MannKind Corporation (NASDAQ:MNKD) dropped -5.84 percent to $10.32 Tuesday on volume of 21.06million shares. The intra-day range of the stock was $10.21 to $10.81. MannKind Corporation (NASDAQ:MNKD) has a market capitalization of $4.01billion.

Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $81.82, for a total value of $409,100.00. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on July 01, 2014 reported a increase of 2.87% to the closing price of $85.29. Its fifty two weeks range is $51.42 -$85.49. The total market capitalization recorded $130.98billion. The overall volume in the last trading session was 11.60million shares. In its share capital, GILD has 1.54billion outstanding shares.

Agenus Inc (NASDAQ:AGEN) announced phase 2 trial results of its Prophage autologous cancer vaccine for glioblastoma multiforme (GBM) today. The results showed that patients who were administered the vaccine as part of their standard care treatment saw an astonishing 2-year increase in their life spans. On Tuesday, shares of Agenus Inc (NASDAQ:AGEN) advanced 10.25% to close the day at $3.55. Company return on investment (ROI) is -581.40% and its monthly performance is recorded as 17.16%.  Agenus Inc (NASDAQ:AGEN) quarterly revenue growth is 7.25%.

Merck & Co Inc (NYSE:MRK) said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children. Merck & Co., Inc. (NYSE:MRK) stock performance was 1.14% in last session and finished the day at $58.51. Traded volume was 8.84million shares in the last session and the average volume of the stock remained 9.96million shares. The beta of the stock remained 0.32. Merck & Co., Inc. (NYSE:MRK) insider ownership is 0.03%.